47,720 Thermo Fisher Scientific Inc. $TMO Shares Purchased by Fenimore Asset Management Inc

Fenimore Asset Management Inc lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 781.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,830 shares of the medical research company’s stock after purchasing an additional 47,720 shares during the quarter. Fenimore Asset Management Inc’s holdings in Thermo Fisher Scientific were worth $36,338,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Polaris Financial Partners bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $32,000. Kilter Group LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $25,000. Legacy Wealth Managment LLC ID lifted its position in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the period. Allied Private Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $26,000. Finally, MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TMO shares. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective for the company. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Scotiabank started coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $635.55.

Thermo Fisher Scientific Stock Down 1.6%

TMO traded down $10.43 during trading on Thursday, hitting $651.63. 2,585,462 shares of the company’s stock traded hands, compared to its average volume of 2,253,558. The stock has a market capitalization of $240.94 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.75 and a beta of 0.87. The company’s 50 day simple moving average is $624.23 and its two-hundred day simple moving average is $539.29. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $694.33. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last quarter. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.